Back to Search
Start Over
Incorporation of Astragalus polysaccharides injection during concurrent chemoradiotherapy in advanced pharyngeal or laryngeal squamous cell carcinoma: preliminary experience of a phase II double-blind, randomized trial
- Source :
- Journal of Cancer Research and Clinical Oncology. 146:33-41
- Publication Year :
- 2019
- Publisher :
- Springer Science and Business Media LLC, 2019.
-
Abstract
- Concurrent chemoradiotherapy (CCRT) is one of the standard treatments for patients with advanced head and neck squamous cell carcinoma (HNSCC). However, CCRT may lead to decreased quality of life (QoL) and treatment compliance. This study aimed to determine the effects of PG2 (Astragalus polysaccharides) injection on CCRT-associated adverse events (AEs) and patients’ compliance with the CCRT course. In this phase II double-blind randomized placebo-controlled trial, PG2 injection (sterile powder form) or placebo was administrated three times per week in parallel with CCRT to patients with HNSCC. The chemotherapy regimen included 50 mg/m2 cisplatin every 2 weeks with daily tegafur–uracil (300 mg/m2) and leucovorin (60 mg/day). The study was terminated prematurely due to the successful launch of a newly formulated PG2 injection (lyophilized form). A total of 17 patients were enrolled. The baseline demographics and therapeutic compliance were comparable between the CCRT/PG2 and CCRT/placebo groups. During CCRT, severe treatment-associated AEs were less frequent in the CCRT/PG2 group than in the CCRT/placebo group. Furthermore, less QoL fluctuations from the baseline during CCRT were noted in the CCRT/PG2 group than in the CCRT/placebo group, with a significant difference in the pain, appetite loss, and social eating behavior. The tumor response, disease-specific survival and overall survival did not differ between the two groups. This preliminary study demonstrated PG2 injection exhibited an excellent safety profile, and has potential in ameliorating the deterioration in QoL and the AEs associated with active anticancer treatment among patients with advanced pharyngeal or laryngeal HNSCC under CCRT. Further research in patients with other cancer types or treatment modalities may widen PG2’s application in clinical settings.
- Subjects :
- Male
0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
Leucovorin
Placebo
law.invention
03 medical and health sciences
0302 clinical medicine
Double-Blind Method
Quality of life
Randomized controlled trial
Polysaccharides
law
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
Humans
Medicine
Uracil
Adverse effect
Laryngeal Neoplasms
Tegafur
Cisplatin
Squamous Cell Carcinoma of Head and Neck
business.industry
Cancer
Pharyngeal Neoplasms
Astragalus Plant
Chemoradiotherapy
General Medicine
Middle Aged
medicine.disease
Head and neck squamous-cell carcinoma
Chemotherapy regimen
030104 developmental biology
030220 oncology & carcinogenesis
Female
business
medicine.drug
Subjects
Details
- ISSN :
- 14321335 and 01715216
- Volume :
- 146
- Database :
- OpenAIRE
- Journal :
- Journal of Cancer Research and Clinical Oncology
- Accession number :
- edsair.doi.dedup.....6715fca839578dd0ae413f809bd7c8bd
- Full Text :
- https://doi.org/10.1007/s00432-019-03033-8